Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with a PD-1 monoclonal antibody as first-line treatment in elderly patients with advanced lung cancer
ChiCTR2100045688Phase 4Recruiting
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- May 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and PD-1 Monoclonal Antibody in non-small cell lung cancer (NSCLC) and bronchial carcinoma, sponsored by Xinxiang Medical University First Affiliated Hospital. Primary endpoints: Progression-free survival, Overall survival and 2 more. Started May 2021; status: recruiting.
02
Drugs
anlotinibPD-1 Monoclonal Antibody
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2100045688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045688.